Prognosis and Results After Resection of Very Large (≥10 cm) Hepatocellular Carcinoma
Few potentially curative treatment options exist besides resection for patients with very large (≥10 cm) hepatocellular carcinoma (HCC). We sought to examine the outcomes and risk factors for recurrence after resection of ≥10 cm HCC.
Perioperative and long-term outcomes were examined for 189 consecutive patients from 1993 to 2004 who underwent potentially curative resection of HCC ≥10 cm (n = 24; 13%) vs. those with HCC <10 cm (n = 165; 87%). Disease-free survival (DFS) and overall survival (OS) were determined by Kaplan–Meier analysis and patient, tumor, and treatment characteristics were compared using univariate and multivariate analysis.
Median follow-up was 34 months. Tumors ≥10 cm were more likely to be symptomatic, of poorer grade, and have vascular invasion (p < 0.05). Twelve patients (50%) underwent an extended resection of more than four hepatic segments or resection of adjacent organs for oncologic clearance (diaphragm-2, inferior vena cava (IVC)-2, median sternotomy-1). Postoperative complications were more common after resection of >10 cm HCC (12/24, 50% vs. 35/165, 21%; p = 0.04). Median DFS was significantly shorter in patients with large HCC (≥10 cm) group compared to patients with smaller HCC (8.4 vs. 38 months; p = 0.001), but overall survival was not different between the two groups (5-year survival 54% vs. 53%; p = 0.43). Seventeen patients (71%) with very large HCC developed recurrences (12 intrahepatic, five systemic); eight of these patients (47%) underwent additional therapy (resection-4, TACE-3, RFA-1). Pathological positive margins and vascular invasion were significant determinants of DFS in tumors ≥10 cm (p < 0.05), but only vascular invasion was an independent risk factor for recurrence after multivariate analysis (HR 0.17; 95% CI: 0.04–0.8). Median OS after recurrence was 24 months.
Surgical resection is the optimal therapy for very large (≥10 cm) HCC. Although recurrences are common after resection of these tumors, overall survival was not significantly different from patients after resection of smaller HCC in this series.
KeywordsHepatocellular carcinoma Resection Vascular invasion Recurrence Ablation Liver transplant
- 3.Taura N, Yatsuhashi H, Hamasaki K, Nakao K, Daikoku M, Ueki T, Yano K, Matsumoto T, Ishibashi H, Eguchi K. Increasing hepatitis C virus-associated hepatocellular carcinoma mortality and aging: Long term trends in Japan. Hepatol Res 2006;88:35–55.Google Scholar
- 4.Monnet E, Collin-Naudet E, Bresson-Hadni S, Minello A, Di Martino V, Carel D, Jooste V, Gagnaire A, Evrard P, Obert-Clerc B, Miguet JP, Hillon P. Place of residence and distance to medical care influence the diagnosis of hepatitis C: a population-based study. J Hepatol 2006;44:499–506.PubMedCrossRefGoogle Scholar
- 7.Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086–1092.PubMedCrossRefGoogle Scholar
- 12.Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, Belghiti J, Ng IO, Yamaoka Y, Lauwers GY, Vauthey JN. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450–457.PubMedCrossRefGoogle Scholar
- 18.Hemming AW, Gallinger S, Greig PD, Cattral MS, Langer B, Taylor BR, Verjee Z, Giesbrecht E, Nakamachi Y, Furuya KN. The hippurate ratio as an indicator of functional hepatic reserve for resection of hepatocellular carcinoma in cirrhotic patients. J Gastrointest Surg 2001;5:316–321.PubMedCrossRefGoogle Scholar
- 20.Pawlik TM, Poon RT, Abdalla EK, Zorzi D, Ikai I, Curley SA, Nagorney DM, Belghiti J, Ng IO, Yamaoka Y, Lauwers GY, Vauthey JN. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005;140:450–457.PubMedCrossRefGoogle Scholar
- 22.Ng KK, Vauthey JN, Pawlik TM, Lauwers GY, Regimbeau JM, Belghiti J, Ikai I, Yamaoka Y, Curley SA, Nagorney DM, Ng IO, Fan ST, Poon RT. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. Ann Surg Oncol 2005;12:364–373.PubMedCrossRefGoogle Scholar
- 23.Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1222 consecutive patients from a prospective database. Ann Surg 2004;240:698–708.PubMedCrossRefGoogle Scholar
- 32.Wakabayashi H, Ishimura K, Okano K, Izuishi K, Karasawa Y, Goda F, Maeba T, Maeta H. Is preoperative portal vein embolization effective in improving prognosis after major hepatic resection in patients with advanced-stage hepatocellular carcinoma? Cancer 2001;92:2384–2390.PubMedCrossRefGoogle Scholar
- 34.Yamasaki S, Hasegawa H, Kinoshita H, Furukawa M, Imaoka S, Takasaki K, Kakumoto Y, Saitsu H, Yamada R, Oosaki Y, Arii S, Okamoto E, Monden M, Ryu M, Kusano S, Kanematsu T, Ikeda K, Yamamoto M, Saoshiro T, Tsuzuki T. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 1996;87:206–211.PubMedGoogle Scholar
- 38.Covey AM, Tuorto S, Brody LA, Sofocleous CT, Schubert J, Tengg-Kobligk H, Getrajdman GI, Schwartz LH, Fong Y, Brown KT. Safety and efficacy of preoperative portal vein embolization with polyvinyl alcohol in 58 patients with liver metastases. AJR Am J Roentgenol 2005;185:1620–1626.PubMedCrossRefGoogle Scholar